DDInter379 DDInter782
Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Cilostazol {u} (Compound) binds {v} (Gene) PDE3A
Cilostazol {u} (Compound) upregulates {v} (Gene) RRP8
Cilostazol {u} (Compound) palliates {v} (Disease) systemic scleroderma
Cilostazol {u} (Compound) downregulates {v} (Gene) PPP2R5E
Cilostazol {u} (Compound) causes {v} (Side Effect) Arthritis
Cilostazol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brivaracetam
Cilostazol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Cilostazol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Adenosine
Cilostazol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etravirine
Cilostazol {u} may lead to a major life threatening interaction when taken with {v} Fondaparinux
Cilostazol (Compound) binds PDE3A (Gene)
Cilostazol (Compound) upregulates RRP8 (Gene)
Cilostazol (Compound) palliates systemic scleroderma (Disease)
Cilostazol (Compound) downregulates PPP2R5E (Gene)
Cilostazol (Compound) causes Arthritis (Side Effect)
Cilostazol may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Cilostazol may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Adenosine
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Cilostazol may lead to a major life threatening interaction when taken with Fondaparinux